Q32 BioFRA:DB0 -0.18%17 ROE % is -69.34% as of Mar. 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,248 Biotechnology companies, Q32 Bio ranks better than 98.96% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Q32 Bio's annualized net income for the quarter that ended in Mar. 2026 was €-26.33 Mil. Q32 Bio's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €37.97 Mil. Therefore, Q32 Bio's annualized ROE % for the quarter that ended in Mar. 2026 was -69.34%.
The historical rank and industry rank for Q32 Bio's ROE % or its related term are showing as below:
FRA:DB0'
s ROE % Range Over the Past 10 Years
Min: 125.06 Med: 125.06 Max: 309.93
Current: 309.93
During the past 5 years, Q32 Bio's highest ROE % was 309.93%. The lowest was 125.06%. And the median was 125.06%.
FRA:DB0's ROE % is ranked better than 98.96% of 1248
companies
in the Biotechnology industry
Industry Median: -38.26
vs FRA:DB0: 309.93
Q32 Bio (FRA:DB0) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Q32 Bio ROE % Related Terms
Q32 Bio ROE % Historical Data
* Premium members only.
The historical data trend for Q32 Bio's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Q32 Bio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's ROE % distribution charts can be found below:
* The bar in red indicates where Q32 Bio's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Q32 Bio (FRA:DB0) has a ROE % of -69.34% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Q32 Bio and its competitors. Over the past decade, Q32 Bio's ROE % has ranged from 125.06 to 309.93. According to the industry distribution chart, Q32 Bio ranks #13 out of 1248 companies in the Biotechnology industry, placing it in the top 1%.
Is Q32 Bio's ROE % too high?
Q32 Bio's current ROE % is -69.34%. Over the past 10 years, this metric has ranged from a low of 125.06 to a high of 309.93. Based on the distribution chart, Q32 Bio ranks #13 out of 1248 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's ROE % compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #13 out of 1248 companies for ROE %. This places Q32 Bio in the top 1% of its industry — outperforming the majority of peers. Historically, Q32 Bio's own ROE % has ranged from 125.06 to 309.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Q32 Bio and its competitors. Q32 Bio's current ROE % is -69.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current ROE % of -69.34%. The current ROE % is -69.34%. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current ROE % is -69.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for FRA:DB0
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DB0 has been successfully added to your 
